F2-isoprostanes As an Indicator and Risk Factor for Coronary Heart Disease

Overview

Journal Free Radic Biol Med

Specialties Biochemistry
Biology
General Medicine

Date 2010 Dec 4

PMID 21126576

Citations 56

Authors

Sean S Davies

L Jackson Roberts 2nd

Affiliations

Soon will be listed here.

Abstract

Coronary heart disease (CHD) is the leading single cause of death in the United States and most Western countries, killing more than 400,000 Americans per year. Although CHD often manifests suddenly as a fatal myocardial infarction, the atherosclerosis that gives rise to the infarction develops gradually and can be markedly slowed or even reversed through pharmacological and lifestyle interventions. These same atherosclerotic processes also drive related vascular diseases such as stroke and peripheral artery disease, and individuals surviving occlusive events often develop additional complications including ischemic cardiomyopathy and heart failure. Therefore, better detection of subclinical atherosclerosis, along with more effective treatments, could significantly reduce the rate of death from CHD and related vascular diseases in the United States. In recent years, oxidation of polyunsaturated fatty acids (PUFAs) in plasma lipoproteins has been postulated to be a critical step in the development of atherosclerosis. If so, then monitoring lipid peroxidation should be a useful indicator of disease risk and progression. This review focuses on the evidence that specific PUFA peroxidation products, the F(2)-isoprostanes, are useful biomarkers that could potentially be utilized as indicators of CHD.

Citing Articles

Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis and In Vitro Efficacy.

Goyzueta-Mamani L, Pagliara Lage D, Barazorda-Ccahuana H, Paco-Chipana M, Candia-Puma M, Davila-Del-Carpio G Molecules. 2025; 30(1.

PMID: 39795229 PMC: 11722285. DOI: 10.3390/molecules30010173.

The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.

Wrobel-Nowicka K, Wojciechowska C, Jachec W, Zalewska M, Romuk E Medicina (Kaunas). 2024; 60(5).

PMID: 38792942 PMC: 11123446. DOI: 10.3390/medicina60050760.

Circulating markers of oxidative stress and risk of incident cardiovascular events in obstructive sleep apnea.

Hirsch Allen A, Peres B, Liu Y, Jen R, Shah A, Laher I Sleep Biol Rhythms. 2024; 20(4):533-540.

PMID: 38468626 PMC: 10899996. DOI: 10.1007/s41105-022-00399-0.

Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging.

Jomova K, Raptova R, Alomar S, Alwasel S, Nepovimova E, Kuca K Arch Toxicol. 2023; 97(10):2499-2574.

PMID: 37597078 PMC: 10475008. DOI: 10.1007/s00204-023-03562-9.

Efficacy of Hydroxytyrosol-Rich Food Supplements on Reducing Lipid Oxidation in Humans.

Bender C, Candi I, Rogel E Int J Mol Sci. 2023; 24(6).

PMID: 36982623 PMC: 10054451. DOI: 10.3390/ijms24065521.

References

de Gaetano G . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001; 357(9250):89-95. DOI: 10.1016/s0140-6736(00)03539-x. View

Cracowski J, Cracowski C, Bessard G, Pepin J, Bessard J, Schwebel C . Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001; 164(6):1038-42. DOI: 10.1164/ajrccm.164.6.2104033. View

Kim J, Hyun Y, Jang Y, Lee B, Chae J, Kim S . Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr. 2008; 88(3):630-7. DOI: 10.1093/ajcn/88.3.630. View

Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R . Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation. 2002; 106(22):2800-5. DOI: 10.1161/01.cir.0000039528.49161.e9. View

Shishehbor M, Zhang R, Medina H, Brennan M, Brennan D, Ellis S . Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease. Free Radic Biol Med. 2006; 41(11):1678-83. PMC: 1945055. DOI: 10.1016/j.freeradbiomed.2006.09.001. View

Brown M, Goldstein J . Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science. 1974; 185(4145):61-3. DOI: 10.1126/science.185.4145.61. View

Crujeiras A, Parra D, Abete I, Martinez J . A hypocaloric diet enriched in legumes specifically mitigates lipid peroxidation in obese subjects. Free Radic Res. 2007; 41(4):498-506. DOI: 10.1080/10715760601131935. View

Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J . Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation. 2004; 109(7):843-8. DOI: 10.1161/01.CIR.0000116761.93647.30. View

Bessard J, Cracowski J, Stanke-Labesque F, Bessard G . Determination of isoprostaglandin F2alpha type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B Biomed Sci Appl. 2001; 754(2):333-43. DOI: 10.1016/s0378-4347(00)00621-6. View

10.

Nakanishi S, Suzuki G, Kusunoki Y, Yamane K, Egusa G, Kohno N . Increasing of oxidative stress from mitochondria in type 2 diabetic patients. Diabetes Metab Res Rev. 2004; 20(5):399-404. DOI: 10.1002/dmrr.469. View

11.

Roberts 2nd L, Oates J, Linton M, Fazio S, Meador B, Gross M . The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med. 2007; 43(10):1388-93. PMC: 2072864. DOI: 10.1016/j.freeradbiomed.2007.06.019. View

12.

Reilly M, Delanty N, Lawson J, FitzGerald G . Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 1996; 94(1):19-25. DOI: 10.1161/01.cir.94.1.19. View

13.

Wang B, Pan J, Wang L, Zhu H, Yu R, Zou Y . Associations of plasma 8-isoprostane levels with the presence and extent of coronary stenosis in patients with coronary artery disease. Atherosclerosis. 2005; 184(2):425-30. DOI: 10.1016/j.atherosclerosis.2005.05.008. View

14.

Wang Z, Ciabattoni G, Creminon C, Lawson J, FitzGerald G, Patrono C . Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther. 1995; 275(1):94-100. View

15.

Kontush A, de Faria E, Chantepie S, Chapman M . A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. Atherosclerosis. 2005; 182(2):277-85. DOI: 10.1016/j.atherosclerosis.2005.03.001. View

16.

Stampfer M, Hennekens C, Manson J, Colditz G, Rosner B, Willett W . Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993; 328(20):1444-9. DOI: 10.1056/NEJM199305203282003. View

17.

Rapola J, Virtamo J, Ripatti S, HUTTUNEN J, Albanes D, Taylor P . Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997; 349(9067):1715-20. DOI: 10.1016/S0140-6736(97)01234-8. View

18.

Stephens N, Parsons A, Schofield P, Kelly F, Cheeseman K, Mitchinson M . Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347(9004):781-6. DOI: 10.1016/s0140-6736(96)90866-1. View

19.

Elizondo A, Araya J, Rodrigo R, Signorini C, Sgherri C, Comporti M . Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biol Res. 2008; 41(1):59-68. DOI: /S0716-97602008000100008. View

20.

Sasaki D, Yuan Y, Gikas K, Kanai K, Taber D, Morrow J . Enzyme immunoassays for 15-F2T isoprostane-M, an urinary biomarker for oxidant stress. Adv Exp Med Biol. 2003; 507:537-41. DOI: 10.1007/978-1-4615-0193-0_82. View